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Analysis of recurrent events with an
associated informative dropout time:
Application of the joint frailty model
Jennifer K. Rogers,a*† Alex Yaroshinsky,b Stuart J. Pocock,c
David Stokard and Janice Pogodae
This paper considers the analysis of a repeat event outcome in clinical trials of chronic diseases in the context
of dependent censoring (e.g. mortality). It has particular application in the context of recurrent heart failure
hospitalisations in trials of heart failure. Semi-parametric joint frailty models (JFMs) simultaneously analyse
recurrent heart failure hospitalisations and time to cardiovascular death, estimating distinct hazard ratios whilst
individual-specific latent variables induce associations between the two processes. A simulation study was carried
out to assess the suitability of the JFM versus marginal analyses of recurrent events and cardiovascular death
using standard methods. Hazard ratios were consistently overestimated when marginal models were used, whilst
the JFM produced good, well-estimated results. An application to the Candesartan in Heart failure: Assessment
of Reduction in Mortality and morbidity programme was considered. The JFM gave unbiased estimates of treat-
ment effects in the presence of dependent censoring.We advocate the use of the JFM for future trials that consider
recurrent events as the primary outcome. © 2016 The Authors. Statistics in Medicine Published by John Wiley &
Sons Ltd.
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1. Introduction
This work is motivated by the need for more appropriate methods of statistical analysis in clinical trials
with recurrent event data such as asthma attacks, cancer recurrences and heart failure hospitalisations,
which we will consider here. Typically, in clinical trials for heart failure, composite outcomes (e.g. heart
failure hospitalisation or cardiovascular (CV) death) are adopted as the primary endpoint as they combine
fatal and non-fatal events, which increases the event rate and avoids multiplicity issues [1]. However,
composite endpoints that only consider the first event are suboptimal for a chronic disease such as heart
failure, which is characterised by recurrent heart failure hospitalisations, because repeat events within
individuals are ignored in analyses [2]. Recurrent hospitalisations are also an indication of worsening
condition, and so by ignoring these repeat events, we do not assess the true burden of the disease.
Methods for the analysis of recurrent events include the Poisson, negative binomial, Andersen–Gill and
Wei-Lin-Weissfeld (WLW) approaches [3–5]. The Poisson model is a commonly misused approach to
determine if rates of an event differ between two treatment groups [6]. The Poisson distribution assumes
that the underlying event rate is the same in all subjects (and follows a Poisson process). This does
not hold in the case of heart failure hospitalisations, where the observed distribution of the number of
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events is markedly more skew than the Poisson distribution. In heart failure, some patients are inherently
more/less frail than others, subsequently presenting with increased/fewer hospitalisations, respectively.
If this overdispersion is ignored, standard errors are likely to be too small resulting in confidence intervals
that are too narrow and an increase in the type I error rate. An alternative approach is to use the negative
binomial distribution, which induces an association between repeat events within individuals through a
random effect term, which is assumed to follow a gamma distribution [7]. The negative binomial assumes
individual-specific Poisson event rates conditional on a random effect for each patient’s true underly-
ing rate. Alternatively, the Andersen–Gill model analyses gap times (i.e. the times between consecutive
events) and is an extension of the Cox proportional-hazards model [8]. In the Cox proportional-hazards
model, each individual’s time to event contributes to the partial likelihood, but in the Andersen-Gill
model, each gap time contributes independently. The WLW method, in contrast, considers each ordered
event in turn as the outcome in a sequence of applications of the Cox proportional-hazards model [9]. The
distinctive feature of theWLWmodel is that each individual’s time at risk for each event (i.e. first, second,
third event etc.) is considered to start at randomisation, so full randomised treatment groups are com-
pared. So in the case of heart failure hospitalisations, time to first hospitalisation would be analysed, and
then total time to second hospitalisation would be analysed separately, including everyone randomised,
even if they hadn’t yet had a first hospitalisation. Analysis continues in this manner giving distinct esti-
mated hazard ratios for each ordered hospitalisation. Both the Andersen–Gill andWLWmethods assume
independence of events, but hospitalisations within individuals are likely to be related to each other, and
so robust standard errors can be used to accommodate heterogeneity [10].
A key characteristic of heart failure is that an increase in hospitalisations for worsening condition is
associated with an increased risk of CV death, and so any censoring due to CV death is not independent
of the recurrent event process [11]. It is important that any analyses focussing on recurrent heart failure
hospitalisations account for the competing risk of CV death. Methods for handling competing risks in
the analysis of time-to-event data are well established [12], but these methods do not take into account
recurrent events of the same type within individuals. The Poisson, negative binomial, Andersen–Gill and
WLW methods do not, in general, incorporate competing risks into the analysis of recurrent events. One
simple strategy for incorporating CV death into analyses of recurrent heart failure hospitalisations is to
consider this outcome as an additional event in the recurrent event process [4]. That is, one considers a
composite of recurrent heart failure hospitalisations and CV death. This updated recurrent event process
can then be analysed using the Poisson, negative binomial, Andersen–Gill and WLW models as before.
Alternatively, the Ghosh and Lin non-parametric method analyses recurrent events whilst allowing for
mortality as informative censoring [13]. This method allows non-parametric inferences for a mean func-
tion in one-sample and two-sample settings, producing only log-rank P-values and not estimating the
treatment effect. Alternatively, the Ghosh and Lin semi-parametric method considers regression models,
which specify multiplicative covariate effects on the mean function allowing for an estimated treatment
effect in analyses [14].
A joint frailty model (JFM) simultaneously analyses recurrent events and an associated time to event
whilst taking into account the relationship between the two processes and is the focus of this article
[15]. In the analysis of heart failure hospitalisations and CV death, this method allows simultaneous
estimation of the effect of treatment on both recurrent heart failure hospitalisations and mortality, under
the assumption that the two processes are independent of one another after conditioning on an individual
specific random effect term.
This paper specifically examines the use of the JFM in the analysis of recurrent heart failure hospital-
isations in the presence of the competing risk of CV death. A simulation study assesses its suitability as
compared with the marginal analysis of time to CV death using the Cox proportional-hazards model and
the WLW and Ghosh and Lin semi-parametric models for the marginal analyses of the recurrent events,
ignoring and incorporating competing risks, respectively. Following this, the methods are applied to two
clinical trials in heart failure: Candesartan in Heart failure: Assessment of Reduction in Mortality and
morbidity (CHARM)-Added and CHARM-Alternative.
2. Data
TheCHARMprogramme comprised three component arms, each considering distinct but complementary
populations [16]. Here, we study two such components, CHARM-Added and CHARM-Alternative trials,
which randomised patients with reduced ejection fraction on or not on angiotensin-converting enzyme
(ACE) inhibitors, respectively, to candesartan versus placebo [17,18]. CHARM-Preserved is not consid-
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Table I. Summary of key outcomes for CHARM-Added and CHARM-
Alternative. ∗Composite of first investigator reported HF hospitalisation or
CV death.
CHARM-Added CHARM-Alternative
Placebo Candesartan Placebo Candesartan
Randomised 1272 1276 1015 1013
Total follow-up (years) 3713 3848 2584 2660
All cause deaths 412 377 296 265
CV deaths 347 302 252 219
Unadjudicated composite∗ 561 497 412 340
⩾ 1 HFH 380 323 289 211
⩾ 2 HFH 187 131 126 94
Number of HFHs:
1 193 192 163 117
2 91 74 58 45
3 37 24 29 21
4 21 14 16 9
5 19 8 8 10
6 6 4 7 3
7 5 3 2 2
8 3 2 3 3
9 1 0 1 0
10 1 2 2 1
11 2 0 0 0
12 1 0 0 0
Total HFH 813 589 579 422
CHARM: Candesartan in Heart failure: Assessment of Reduction in Mortality and
morbidity.
ered here as this trial considered patients presenting with milder heart failure. Table I summarises the
key outcomes for the CHARM-Added and CHARM-Alternative trials. CHARM-Added followed 2548
patients for a median follow-up of 41 months, and CHARM-Alternative enrolled 2028 patients followed
for a median of 33.7 months. There were 649 and 471 CV deaths in CHARM-Added and in CHARM-
Alternative, respectively. In CHARM-Added, 703 patients presented with a total of 1402 heart failure
hospitalisations, of which 699 (49.9%) were repeats. There were 500 patients in CHARM-Alternative
with at least one heart failure hospitalisation, and there were 1001 hospitalisations in total, with 501
(50.0%) being repeats.
The pre-defined primary endpoint for both trials was the composite of first heart failure hospitalisation
and CV death. This composite endpoint was analysed as time to first event using the Cox proportional-
hazards model. As this primary analysis considered only the first hospitalisation for worsening heart
failure, only first hospitalisations were adjudicated by an independent clinical-event committee, and
any repeats within individuals remained unadjudicated. Hence, to ensure a fair comparison between
methodologies, the primary analysis was repeated using the investigator reported first heart failure
hospitalisations for each patient.
3. Modelling strategies
3.1. Marginal models for recurrent and terminal events
We began the simulation study by considering the composite endpoint of first heart failure hospitalisation
and CV death as this remains a common practice in the analysis of heart failure trials. We analysed the
time to the composite endpoint using the Cox proportional-hazards model [19]. This model was also used
to marginally analyse time to CV death. Under this model, the hazard function for individual i = 1,… , n
is given, in general, by the following:
𝜆i(t) = exp{𝛽zi}𝜆0(t),
© 2016 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 2195–2205
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where 𝜆0(t) is the baseline hazard function, zi denotes treatment allocation (zi = 1 for active treatment
and zi = 0 for control) and 𝛽 is the associated regression coefficient. The associated hazard ratios are
given by HRCOMP = exp{𝛽COMP} and HRCPH = exp{𝛽CPH} for the composite endpoint and CV death,
respectively.
The composite of recurrent heart failure hospitalisations and CV death was analysed using the WLW
model, and the Ghosh and Lin semi-parametric model was used to analyse the recurrent heart failure
hospitalisations adjusted formortality. TheWLWmodel is an elaboration of the Cox proportional-hazards
model that allows recurrent time to event outcomes to be analysed [9]. This model limits analysis to the
first K events (either heart failure hospitalisations or CV death) within each patient, and each event is
used as the outcome in a distinct application of the Cox proportional-hazards model:
𝜆ik(t) = exp{𝛽kzi}𝜆0k(t), k = 1,… ,K.
The hazard for individual i allocated to treatment zi of event k at time t is given by 𝜆ik(t). The total num-
ber of events per person that are included in the analyses, K, is typically chosen such that 𝛽k can be
estimated with a useful degree of precision. The WLWmodel also estimates the ‘average effect’ of treat-
ment on recurrent heart failure hospitalisations and CV death, 𝛽 which can be calculated as a weighted
average of 𝛽k, the weighting aimed at ensuring the minimum variance for the estimate. This method
assumes that all heart failure hospitalisations are independent, which is unrealistic as hospitalisations
within the same individual are likely to be related to each other. Furthermore, data of this sort are likely
to be heterogeneous, with some patients being inherently more/less frail than others, subsequently pre-
senting with increased/fewer hospitalisations, respectively. Robust standard errors are used to allow for
this dependency and heterogeneity. The average hazard ratio is then given by HRWLW = exp{𝛽WLW}. The
unique feature of theWLWmodel is that for each of the K heart failure hospitalisations, each individual’s
time at risk for that particular hospitalisation is assumed to commence at the time of randomisation for
that patient. So this means that as soon as a patient is randomised, they are included in the risk sets for
all hospitalisations.
The Ghosh and Lin semi-parametric method considers the marginal expected number of recurrent
heart failure hospitalisations up to some particular time, t, acknowledging the fact that death is a terminal
event after which no further recurrent hospitalisations can be experienced [14]. This means that although
a patient stays in the risk set beyond time to death, their associated recurrent hospitalisation count stays
constant, fixed at whatever value it was just prior to death. Let N∗i (t) be the number of heart failure hos-
pitalisations over the time interval [0, t] for individual i and let Di be the time of death, so that N∗i (t) does
not jump after Di. Treatment is assumed to have a multiplicative effect on the baseline mean function,
whilst the stochastic structure of the recurrent hospitalisations process is left completely unspecified. This
means that there are no restrictions on the nature of dependence amongst repeat heart failure hospitalisa-
tions within an individual or between hospitalisations and death. Define the marginal expected number
of recurrent heart failure hospitalisations for person i up to t, associated with zi and which acknowledges
that no further recurrences occur after death as 𝜇i(t) = E{N∗i (t) ∣ zi}, which can be formulated through
the semi-parametric model:
𝜇i(t) = exp{𝛽zi}𝜇0(t),
where 𝜇0(t) is an unspecified continuous function. This model assumes time-invariance of the treatment
effect, and the hazard ratio is given by HRGL = exp{𝛽GL}.
3.2. Joint frailty model
The JFM is a semi-parametric model that accounts for the dependence between recurrent heart failure
hospitalisations and death through a patient-specific frailty term [15]. This analyses the recurrent heart
failure hospitalisations and times to CV death simultaneously with a latent variable (frailty) inducing an
association between the two event processes. Recall that the Ghosh and Lin approach treats death as a
terminating event, meaning that patients who have died remain in the risk set for future heart failure hos-
pitalisations with their count remaining constant. Care needs to be taken with this method therefore, as an
increase in the mortality rate will consequently result in a decrease in the expected number of heart fail-
ure hospitalisations for an individual. This model reflects the fact that one way in which treatment may
reduce the number of hospitalisations is by increasing the mortality rate. Thus, if a treatment decreases
both the heart failure hospitalisation rate and the mortality rate, estimated treatment effects for the hospi-
talisation rates may be attenuated under the Ghosh and Lin model. Conversely, the JFM treats CV death
as a competing risk with patients then being censored from further repeat heart failure hospitalisations.
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Hospitalisations that patients would have experienced had they not died are treated as missing data, and
the JFM captures this ‘lost information’ in the estimation of underlying event rates and treatment effects.
The JFM takes into account the increased risk of CV death because of recurrent heart failure hospital-
isations and also takes into account the competing risk of death when considering the recurrent event
process, but assumes that the two outcomes are independent of each other conditional on the frailty term.
Any non-CV deaths are handled as non-informative censoring.
Define Ti0 = 0 and let Ti1,Ti2,… ,TiNi be the recurrent event times for person i, where Ni is the number
of recurrent events before Xi =min(Ci,Di), the minimum of an independent censoring time Ci and a
dependent CV death time Di. The JFM is defined through the hazard functions for the recurrent event
process and CV death:
ri(t ∣ 𝜔i) = 𝜔i exp{𝛽1zi}r0(t) = 𝜔iri(t)
𝜆i(t ∣ 𝜔i) = 𝜔𝛼i exp{𝛽2zi}𝜆0(t) = 𝜔
𝛼
i 𝜆i(t).
The recurrent heart failure hospitalisations hazard function for the ith patient conditional on the patient-
specific random frailty, 𝜔i, is given by ri and is proportional to the baseline intensity function, r0. The
conditional hazard function for time to CV death for patient i is given by, 𝜆i, with the baseline hazard
given by 𝜆0, and 𝛽1, 𝛽2 are the regression coefficients associated with treatment covariate zi. Patient-
specific independent random effects are denoted by𝜔i and are most commonly and conveniently assumed
to follow a gamma distribution with mean 1 and variance 𝜃. The correlation of the recurrent events is
quantified by 𝜃, with higher values corresponding to greater within-patient correlation and also greater
between-patient variability. The parameter 𝛼 determines the relationship between the recurrent heart fail-
ure hospitalisations and time to CV death. When 𝛼 < 0, higher frailty will result in a greater risk of
recurrence and lower risk of terminal event (i.e. a negative correlation between the frailties), and when
𝛼 > 0, higher frailty will result in a greater risk of recurrence and is associated with a higher risk of CV
death (i.e. a positive correlation between the frailties). When 𝛼 = 1, the impact of frailty is identical on
recurrent and terminating events, and 𝛼 = 0 means that the recurrent event process is independent of CV
death, and the two outcomes can be analysed separately.
Let tij and xi be the observed recurrent event times and follow-up, respectively. Denote by 𝛿ij and Δi,
the indicator of the recurrent event at time tij and the indicator of CV death at time xi, respectively. The
likelihood for person i is then given by the following:
Li = ∫
𝜔i
Ni∏
j=1
[
𝜔iri(tij)
]𝛿ij exp
{
∫
xi
0
𝜔iri(t)dt
}[
𝜔𝛼i 𝜆i(xi)
]Δi exp
{
∫
xi
0
𝜔𝛼i 𝜆i(t)dt
}
f𝜃(𝜔i)d𝜔i.
Adopting piecewise constant hazards for the recurrent events and CV death allows estimation of the
likelihood by Gaussian quadrature [20]. The implementation of Gaussian quadrature techniques is
incorporated into Proc NLMIXED of SAS 9.1 [21]. The joint model gives two distinct hazard ratios:
HRJFM1 = exp{𝛽1} is the hazard ratio associated with the effect of treatment on the recurrent event rate,
and HRJFM2 = exp{𝛽2} is the terminal event hazard ratio.
4. Simulation study
Various data scenarios were used to evaluate the power and estimated treatment effects using the mod-
elling strategies described in the previous section. Heart failure hospitalisation rates and CV death rates
for a simulated cohort were generated with parameters comparable with those observed in the COMPAN-
ION and CUPID Phase II heart failure studies [22,23]. Data sets were simulated with 300 subjects in each
group and varied frailty variance, 𝜃, (1–3.5), frailty exponent, 𝛼 (0–3), recurrent (0.9–1.2) and terminal
(25–31%) annual event rates around expected values, as well as sensible treatment effect sizes (0.67–
0.75). The rate of independent censoring, 𝜃C, was set at 5%. Greater frailty variance, 𝜃, corresponds to
stronger correlation between recurrent event gap times and larger between subjects variation with respect
to event recurrences and terminal events. Zero variance corresponds to independent recurrent events.
Subjects assigned to treatment group with probability 0.5 and different distributions for 𝜔i were con-
sidered: 𝜔i ∼gamma(𝜃, 𝜃) and log(𝜔i) ∼Normal(0, 𝜃). Time to independent censoring, time to terminal
event and recurrent event gap times were generated using an exponential distribution with rate parameters
1/𝜆C, 1/𝜆i(t ∣ 𝜔i) and 1∕ri(t ∣ 𝜔i), respectively, where the parameter 𝜆C was assumed to be independent of
© 2016 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 2195–2205
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the recurrent heart failure hospitalisations. The parameter 𝜆i(t ∣ 𝜔i) was based on the simulation param-
eters: 𝜆0(t), HR𝜆 (terminal event hazard ratio), generated frailty, 𝜔i, and frailty exponent, 𝛼. If either the
censoring or terminal time was greater than some specified maximum follow-up time, tMAX , the subject
was considered censored at tMAX .
The parameter ri(t ∣ 𝜔i) was based on the simulation parameters: r0(t), HRr (recurrent event hazard
ratio) and generated frailty, 𝜔i. Recurrent event gap times were added to the previous event time (or 0
if no previous event) to arrive at the current event time. Generation of recurrent event times for a given
subject continued until the time of censoring, or time of CV death (whichever is sooner) was exceeded.
If a recurrent event time was equal to the CV death time, the time was assigned to CV death. For each
simulation run, defined by a unique combination of parameter values, there were 500 simulated data
sets. Mean estimated hazard ratios were calculated over all 500 runs, and power was calculated as the
proportion of runs for which the estimated hazard ratio significantly differed from 1 with significance
level 0.05.
Table II presents the treatment effect estimates (hazard ratios) for the composite endpoint, heart failure
hospitalisations and CV death using simulation run data generated with a gamma frailty. For recur-
rent hospitalisations, marginal (WLW and Ghosh and Lin semi-parametric) and JFMs are compared,
which are in turn compared with the results arising from the analysis of the composite of first heart fail-
ure hospitalisation and CV death. While for CV death, the JFM is compared with the traditional Cox
proportional-hazards model. When 𝛼 = 0 (indicating that recurrent and terminal events are independent),
the Cox model and JFM produced identical estimates as expected, and so results for this data scenario
are not presented in Table II. The difference in hazard ratios for CV death, estimated under the different
modelling strategies, increased substantially with 𝛼 becoming larger. When 𝛼 = 3 (meaning that the two
frailties are positively correlated) and the hazard ratio for CV death was HR𝜆 = 0.67, we see that the
hazard ratio estimates from the traditional Cox proportional hazards model were in the range 0.84–0.91,
whereas for the JFM, the estimates remained within 0.66–0.69. When the correlation between recurrent
and terminal events was strong, the proportional hazards assumption in the traditional Cox model was
substantially violated, and the respective estimated hazard ratios were biased. When 𝛼 = 0.5, however,
the correlation between recurrent and terminal events was much weaker, and the bias in the estimates
obtained from the Cox proportional-hazards model decreased substantially.
Table II. Simulation results, values are estimated hazard ratio (percentage power).HRCOMP: hazard ratio from
the Cox proportional-hazards model for the composite of first heart failure hospitalisation and cardiovascular
death.HRWLW ,HRGL,HRJFM1: hazard ratios fromWLW,Ghosh and Lin and joint frailtymodels respectively for
recurrent heart failure hospitalisations.HRCPH ,HRJFM2: hazard ratios from Cox proportional-hazards and joint
frailty models respectively for time to cardiovascular death. 𝜃, 𝛼, r0, 𝜆0, 𝜆C: frailty variance, frailty exponent,
baseline annual recurrent event rate, baseline annual terminal event rate and annual independent censoring
rate respectively.
Simulation parameters Composite Recurrent events Terminal event
𝜃 𝛼 r0 𝜆0 𝜆C HRr HR𝜆 HRCOMP HRWLW HRGL HRJFM1 HRCPH HRJFM2
3.5 3 0.9 31% 5% 0.67 0.67 0.87 (23) 0.87 (35) 0.76 (49) 0.68 (53) 0.91 (8) 0.68 (12)
3.5 3 1.2 31% 5% 0.67 0.67 0.87 (26) 0.87 (38) 0.76 (53) 0.70 (48) 0.91 (8) 0.69 (10)
3.5 1 0.9 31% 5% 0.67 0.67 0.84 (29) 0.83 (46) 0.81 (28) 0.69 (54) 0.79 (36) 0.66 (44)
3.5 1 1.2 31% 5% 0.67 0.67 0.84 (33) 0.83 (50) 0.81 (32) 0.69 (55) 0.77 (37) 0.65 (39)
3.5 0.5 0.9 31% 5% 0.67 0.67 0.81 (40) 0.80 (62) 0.79 (35) 0.71 (52) 0.72 (54) 0.67 (57)
3.5 0.5 1.2 31% 5% 0.67 0.67 0.82 (40) 0.80 (67) 0.79 (37) 0.71 (53) 0.71 (55) 0.67 (58)
1.45 3 0.9 25% 5% 0.67 0.67 0.80 (52) 0.83 (62) 0.72 (73) 0.68 (77) 0.86 (15) 0.67 (16)
1.45 3 1.2 31% 5% 0.67 0.67 0.82 (48) 0.85 (62) 0.73 (81) 0.67 (83) 0.86 (15) 0.66 (17)
1.45 1 0.9 25% 5% 0.67 0.67 0.77 (66) 0.77 (80) 0.72 (69) 0.68 (80) 0.71 (50) 0.66 (50)
1.45 1 1.2 31% 5% 0.67 0.67 0.80 (63) 0.82 (85) 0.76 (77) 0.70 (87) 0.72 (54) 0.65 (56)
1.45 0.5 0.9 25% 5% 0.67 0.67 0.76 (68) 0.76 (88) 0.71 (72) 0.69 (77) 0.68 (57) 0.67 (58)
1.45 0.5 1.2 31% 5% 0.67 0.67 0.77 (72) 0.80 (92) 0.72 (75) 0.69 (84) 0.68 (66) 0.67 (67)
1 3 1.2 31% 5% 0.67 0.67 0.79 (69) 0.83 (74) 0.72 (88) 0.67 (91) 0.84 (23) 0.66 (23)
1 3 1.2 31% 5% 0.67 0.75 0.79 (64) 0.83 (74) 0.70 (91) 0.67 (91) 0.88 (14) 0.75 (14)
1 1 1.2 31% 5% 0.67 0.67 0.76 (77) 0.78 (93) 0.72 (85) 0.68 (91) 0.71 (58) 0.67 (57)
1 1 1.2 31% 5% 0.67 0.75 0.77 (70) 0.80 (90) 0.70 (89) 0.68 (90) 0.78 (37) 0.75 (35)
1 0.5 1.2 31% 5% 0.67 0.67 0.75 (83) 0.77 (95) 0.70 (88) 0.68 (93) 0.68 (67) 0.66 (68)
1 0.5 1.2 31% 5% 0.67 0.75 0.76 (77) 0.79 (92) 0.70 (88) 0.68 (92) 0.76 (42) 0.75 (42)
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The hazard ratios for the recurrent heart failure hospitalisations were also very well estimated by the
JFM, while they are notably overestimated (attenuated to the null) when marginal models were used.
Each of the estimated treatment effects, however, did demonstrate a directionally similar effect, which
would make them useful as sensitivity analyses. Looking at the marginal models for recurrent events, the
Ghosh and Lin semi-parametric model performed better than theWLW and composite endpoint analyses.
Interestingly, the Cox proportional-hazards model and the WLW performed very similarly in terms of
bias but, unsurprisingly, the WLW displayed greater power. The impact of frailty on power can also be
seen in Table II. Larger values of frailty variance, 𝜃, correspond to greater within-patient correlation (and
greater between-patient variability) which resulted in lower power in all of the models considered. Strong
correlations between recurrent hospitalisations within individuals meant that the amount of information
contributed by an additional event for a particular patient was reduced, leading to lower power. Note that
these scenarios were powered for recurrent events and not mortality.
The JFM was also found to be robust to mis-specification of the frailty distribution, with good agree-
ment between the simulation parameters and subsequent estimates when the data were generated with a
log-Normal frailty and analysed using a gamma distribution (results not shown).
5. Application
The primary endpoint in the CHARM-Added and CHARM-Alternative trials was the composite of first
heart failure hospitalisation and CV death, analysed as time to first event using the Cox proportional-
hazardsmodel [17,18]. Using the investigator reported heart failure hospitalisations, for CHARM-Added,
there were 561 and 497 patients with the primary endpoint in the placebo and candesartan groups respec-
tively, yielding a hazard ratio of 0.833 (95% confidence interval (CI) 0.74-0.94, P=0.003) and 412
versus 340 patients in the placebo and candesartan groups respectively in CHARM-Alternative, with an
estimated hazard ratio of 0.772 (95% CI 0.67-0.89, P=0.0004).
The Ghosh and Lin non-parametric estimates of the cumulative incidence of heart failure hospitalisa-
tions per 100 patients, allowing for mortality, for CHARM-Added and CHARM-Alternative are shown in
Figure 1. Both plots show immediate separation of the two treatment group curves with the candesartan
group having consistently fewer hospitalisations than the placebo group. For CHARM-Added, there
appears to be continuous divergence of the two curves whereas for CHARM-Alternative, there appears
to be more rapid divergence for the first year, which then slows beyond that. As the Ghosh and Lin semi-
parametric model was found to be less biased than theWLW in the simulation study, results from analyses
of CHARM-Added and CHARM-Alternative using this model are in Table III alongside results from the
JFM. Both analyses estimated a highly statistically significant reduction in the hazard for hospitalisation
for worsening heart failure because of candesartan. A comparatively attenuated non-significant reduction
in the hazard for CV death was also observed.
A small difference in estimates was observed when using the Ghosh and Lin semi-parametric model
as compared with the JFM. In this application, however, the observed bias in using the marginal
model compared with the JFM was not so severe that conclusions about the treatment effects would be
Figure 1. Ghosh and Lin cumulative incidence per 100 patients for recurrent heart failure hospitalisations for
A: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added and B:
CHARM-Alternative.
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Table III. Results from application to CHARM-Added and CHARM-Alternative.HRGL,
HRJFM1: hazard ratios from Ghosh and Lin and joint frailty models respectively for recur-
rent heart failure hospitalisations. HRCPH , HRJFM2: hazard ratios from Cox proportional-
hazards and joint frailty models respectively for time to CV death. 𝜃, 𝛼: frailty variance
and frailty exponent respectively.
CHARM-Added CHARM-Alternative
Estimate 95% CI P-value Estimate 95% CI P-value
HRGL 0.683 0.57-0.82 <0.0001 0.687 0.55-0.86 0.0008
HRJFM1 0.650 0.53-0.80 <0.0001 0.608 0.49-0.76 <0.0001
HRCPH 0.842 0.72-0.98 0.029 0.847 0.71-1.02 0.072
HRJFM2 0.839 0.70-1.01 0.065 0.851 0.68-1.07 0.172
𝜃 (SE) 3.751 (0.208) 3.452 (0.207)
𝛼 (SE) 0.688 (0.054) 0.846 (0.069)
CHARM, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity.
Figure 2. Kaplan–Meier curves for time to cardiovascular (CV)-Death for A: Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM)-Added, and B: CHARM-Alternative.
misleading. The marginal analysis of CV death using the Cox proportional-hazards model gave estimates
that were in line with the JFM. The Kaplan–Meier curves for time to CV death for CHARM-Added and
CHARM-Alternative can be seen in Figure 2. Those treated with candesartan consistently have fewer
CV deaths than those in the placebo group. For CHARM-Added, the survival curves appear to be similar
for the first 6 months with continued separation thereafter, and for CHARM-Alternative, there is a more
marked difference for the first 18 months, after which the curves converge slightly. The reason for this
agreement could possibly be that there was only a modest, non-significant treatment difference for CV
death. Also, note the small estimated value of 𝛼, and recall that in the simulation study, it was observed
that estimate hazard ratios were generally in agreement amongst the marginal and JFMs for 𝛼 = 0.5.
Overall, estimates of hazard ratios for recurrent heart failure hospitalisations and hazard ratios for CV
death were very similar between CHARM-Added and CHARM-Alternative. For patients with reduced
ejection fraction on or not on ACE inhibitors (CHARM-Added and CHARM-Alternative respectively),
treatment with candesartan reduced the rate of recurrent hospitalisations by 35% and 39%, respectively,
and reduced the hazard for CV death by 16% and 15%, respectively. Estimates of the frailty variance,
𝜃, were large in each of the analyses, suggesting high levels of within-subject correlation for recurrent
events and substantial heterogeneity in between-subject heart failure hospitalisation hazards.
6. Discussion
The JFM provides good reproducible treatment effect estimates for various data scenarios when recurrent
and terminal events are correlated. Bias in estimated treatment effects through the use of marginal models
in the presence of correlation between recurrent and terminal events have been clearly observed and was
found to increase with stronger correlations.
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The frailty model is different from the marginal models, and the proportionality assumption generally
cannot hold for both frailty and marginal models at the same time. When recurrent and terminal events
are not independent (i.e. 𝛼 ≠ 0) and when between-patient effects are accounted for by a multiplicative
frailty, the proportional hazards assumption is violated and so hazard ratios from the marginal model may
be substantially biased. The stronger the correlation between recurrent and terminal events, the larger
the difference between estimated treatment effects from the marginal and frailty models. The interpreta-
tion of treatment effects under the marginal and frailty model are different, and so estimated regression
coefficients may be substantially different too.
The estimated hazard ratios for recurrent events from the Ghosh and Lin semi-parametric model, which
accounted for the competing risk of CV death, agreed better with those from the JFM than estimates
from the WLW approach. Overestimates of the treatment effect under this model were likely due to the
differences in the model interpretations (marginal versus frailty models). In general, the Ghosh and Lin
model provides a marginal estimate of the treatment effect for recurrent events that is adjusted by the
presence of a terminal event, but does not explicitly estimate the effect of treatment on the hazard of the
terminal event. If interest lies in the effect of treatment on both recurrent and terminal events, the JFM
would clearly be more suitable.
Justification for the use of the WLW model in the analysis of recurrent events is driven by the fact
that treatment effect estimates are based upon comparisons of the complete treatment groups for each
ordered event in turn as all randomised patients are included in the risk set for each distinct event [24].
Application of theWLWmethod is also recommended as the nature of the relationship between recurrent
events needs not be known, but this failure to model within-patient associations results in inefficiencies
in estimates of treatment effects. Further criticisms of the WLW model are that this approach includes
patients in the risk set for the kth event who might not necessarily have presented with the k − 1th event,
thus ignoring the ordered nature of events. Additionally, the treatment effect of the kth event will carry
through to subsequent events, thus influencing estimates of treatment effects on later events. Also, note
that in order to obtain an overall estimate of treatment effect when using the WLW method, a weighted
average of the individual estimated hazard ratios must be calculated, and it is unclear as to how this
‘average effect’ should be interpreted.
This article considered a derivation of the JFM that depended on a single covariate: treatment effect.
This model can easily be extended to consider a vector of covariates by considering the following hazard
functions for the recurrent event process and CV death:
ri(t ∣ 𝜔i) = 𝜔i exp{𝜷′1𝐙i}r0(t) = 𝜔iri(t)
𝜆i(t ∣ 𝜔i) = 𝜔𝛼i exp{𝜷
′
2𝐙i}𝜆0(t) = 𝜔
𝛼
i 𝜆i(t),
where 𝜷1, 𝜷2 are p × 1 vectors of regression coefficients associated with vectors of covariates 𝐙1 and
𝐙2, respectively. Additionally, the formulation of the JFM presented in this article considered a single
frailty term, 𝜃, with the effect of this frailty on the two processes being allowed to differ through the
use of 𝛼. Alternatively, each of the two event processes could be specified with their own random effects
with a covariance allowed between the two. An example of a suitable distribution is the Wicksell–Kibble
bivariate gamma, which allows specification of marginal gamma distributions which are correlated [25].
We note that although the JFM provides good reproducible estimates of the treatment effect, formal
examination of the goodness of fit between expected and observed values has not been examined here.
This would not be a straightforward task given the presence of dependent censoring and would be an
interesting area for further research.
One of the treatment effects estimated in the semi-parametric JFM is the hazard ratio for recurrent
events. In the case of heart failure hospitalisations, this can be interpreted as an increase/decrease in the
instantaneous probability of an event recurrence at a particular point in time, subject to a patient’s past
event history. Alternatively, parametric formulations of the JFM consider the effect of treatment on an
individual’s recurrent event rate, that is the ratio of rates of heart failure hospitalisations [4, 26]. These
rate ratios for recurrent events have a more clinically intuitive interpretation than a hazard ratio for a
repeat event.
In conclusion, we intend that the analyses and results presented here indicate a way forward for
trials of chronic diseases that are characterised by recurrent events in the presence of dependent censor-
ing. We encourage further case studies considering the application of the JFM, so that in due course,
these methods become a routinely accepted key component in the analysis and reporting of trials of
chronic diseases. What matters is that trials of chronic diseases that are characterised by recurrent
© 2016 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 2195–2205
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events stop giving priority to inefficient methods (composite endpoints that only consider time to first
event) and make better use of the totality of evidence whilst accounting for competing risks that may also
be present.
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